Literature DB >> 12590638

Impact of successful transsphenoidal surgery on cardiovascular risk factors in acromegaly.

Marie-Lise Jaffrain-Rea1, Giuseppe Minniti, Carlo Moroni, Vincenzo Esposito, Elisabetta Ferretti, Antonio Santoro, Tommaso Infusino, Guido Tamburrano, Giampaolo Cantore, Rosario Cassone.   

Abstract

BACKGROUND: Cardiac abnormalities develop in patients with acromegaly as a consequence of effects of GH/IGF-I on the heart and related cardiovascular risk factors.
OBJECTIVE: To evaluate the possible contribution of postoperative variations in blood pressure (BP), glucose tolerance and insulin sensitivity to the cardiac improvement reported in patients who have been cured of acromegaly.
DESIGN: Thirty-one patients with acromegaly were studied before and 6 Months after successful transsphenoidal surgery, defined by normal age-related IGF-I concentrations and glucose-suppressed GH concentrations <1 microg/l.
METHODS: Cardiovascular parameters were assessed by Doppler echocardiography and 24-h ambulatory blood pressure monitoring. Insulin sensitivity indexes were calculated on the basis of fasting and post-load glycaemia and insulinaemia and referred to as HOMA(ISI) and OGTT(ISI), respectively.
RESULTS: Successful surgery was confirmed to improve left ventricular mass index (LVMI) and diastolic filling significantly. Mean 24-h systolic BP values decreased (P=0.009) and BP rhythm was restored in 12 of 15 patients with a blunted preoperative profile. Glucose tolerance normalized in patients with preoperative glucose intolerance (n=7) or diabetes mellitus (n=3). HOMA(ISI) and OGTT(ISI) increased (P=0.0001 for each parameter), indicating a marked improvement in insulin sensitivity. The postoperative reduction in LVMI correlated with increased insulin sensitivity (P<0.001 for both indexes), but not with other parameters. Improved diastolic filling correlated with the reduction in LVMI.
CONCLUSIONS: Successful surgery in patients with acromegaly induces a significant improvement in haemodynamic and metabolic risk factors. This study suggests a direct link between insulin resistance and acromegalic cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12590638     DOI: 10.1530/eje.0.1480193

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  17 in total

1.  Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature.

Authors:  Claire Briet; Mirela Diana Ilie; Emmanuelle Kuhn; Luigi Maione; Sylvie Brailly-Tabard; Sylvie Salenave; Bertrand Cariou; Philippe Chanson
Journal:  Endocrine       Date:  2018-11-05       Impact factor: 3.633

2.  Preoperative octreotide therapy and surgery in acromegaly: associations between glucose homeostasis and treatment response.

Authors:  R Helseth; S M Carlsen; J Bollerslev; J Svartberg; M Øksnes; S Skeie; S L Fougner
Journal:  Endocrine       Date:  2015-07-16       Impact factor: 3.633

3.  Prospective study of surgical treatment of acromegaly: effects on ghrelin, weight, adiposity, and markers of CV risk.

Authors:  Carlos Reyes-Vidal; Jean Carlos Fernandez; Jeffrey N Bruce; Celina Crisman; Irene M Conwell; Jane Kostadinov; Eliza B Geer; Kalmon D Post; Pamela U Freda
Journal:  J Clin Endocrinol Metab       Date:  2014-08-19       Impact factor: 5.958

Review 4.  The cardiovascular system in growth hormone excess and growth hormone deficiency.

Authors:  G Lombardi; C Di Somma; L F S Grasso; M C Savanelli; A Colao; R Pivonello
Journal:  J Endocrinol Invest       Date:  2012-11-12       Impact factor: 4.256

Review 5.  Improvement of cardiac parameters in patients with acromegaly treated with medical therapies.

Authors:  Annamaria Colao
Journal:  Pituitary       Date:  2012-03       Impact factor: 4.107

Review 6.  Surgery induced hypopituitarism in acromegalic patients: a systematic review and meta-analysis of the results.

Authors:  Pedro Carvalho; Eva Lau; Davide Carvalho
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

7.  Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) Study.

Authors:  A Giustina; T Mancini; P F Boscani; E de Menis; E degli Uberti; E Ghigo; E Martino; F Minuto; A Colao
Journal:  J Endocrinol Invest       Date:  2008-08       Impact factor: 4.256

Review 8.  Acromegalic cardiomyopathy: a review of the literature.

Authors:  M P Matta; P Caron
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

Review 9.  Radiation techniques for acromegaly.

Authors:  Giuseppe Minniti; Claudia Scaringi; Riccardo Maurizi Enrici
Journal:  Radiat Oncol       Date:  2011-12-02       Impact factor: 3.481

10.  Stereotactic Irradiation of GH-Secreting Pituitary Adenomas.

Authors:  G Minniti; C Scaringi; D Amelio; R Maurizi Enrici
Journal:  Int J Endocrinol       Date:  2012-02-22       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.